Japan relies almost entirely on China for the APIs of β-lactam antibiotics. These drugs are essential for treating infectious diseases…
HOME > TOP STORIES
TOP STORIES
-
ACADEMIA Ex-Novartis Employee Manipulated Blood Pressure Data in JIKEI Study: Univ. Probe
July 31, 2013
-
BUSINESS Novartis’s Third-Party Probe Finds “No Evidence” Indicating Data Falsification by Ex-Employee; Truth behind Diovan Woe Not Yet Uncovered
July 30, 2013
-
REGULATORY PAFSC’s Second Committee Recommends Approval for Bronchial Asthma Treatment Flutiform, Others
July 29, 2013
-
ORGANIZATION Red Cross Hospitals to Share Information on Drug Discount Rates
July 29, 2013
-
REGULATORY MHLW-MEXT Joint Committee Agrees to Require Researchers to Store Clinical Research Data for Long Periods
July 26, 2013
-
BUSINESS OncoTherapy, Panasonic Healthcare to Codevelop Immune Monitoring System to Evaluate Effects of Cancer Vaccines
July 26, 2013
-
REGULATORY MHLW Might Submit Bill on Online OTC Sales to Extraordinary Diet Session: PFSB Head
July 25, 2013
-
BUSINESS Otsuka to Develop Sensor-Embedded Abilify to Improve Drug Compliance
July 24, 2013
-
REGULATORY Pilot Program for Japan-Version “Compassionate Use” System to Begin at National Cancer Center
July 23, 2013
-
REGULATORY 1st Committee to Discuss Approval of New Products Including Janssen’s Extended Release Schizophrenia Treatment
July 23, 2013
-
REGULATORY MHLW Mulls “Ultra-Orphan” Drug System; Designation Might Become Possible with Pre-Clinical, Healthy Subject Data
July 22, 2013
-
REGULATORY US Aims for Lifting of Ban on Mixed Care: Prof. Murakami of Yamagata University
July 22, 2013
-
ORGANIZATION FPMAJ Settles on Industry View for TPP, Demands Intellectual Property Protection on Par with Japanese Rules
July 19, 2013
-
REGULATORY South Korean MOHW Officials Announce Roadmap for South Korea to Become No. 7 Worldwide in New Drug Development by 2020
July 19, 2013
-
BUSINESS Pfizer Paid 23.9 Billion Yen to Physicians, Medical Institutions in FY2012; 1st Disclosure under JPMA Guidelines
July 18, 2013
-
ACADEMIA University’s Seriousness to Unravel Diovan Saga Called into Question
July 17, 2013
-
REGULATORY 2nd Committee on Drugs to Discuss Approval for Asthma Treatment Flutiform on July 26
July 17, 2013
-
REGULATORY MHLW, US FDA to Exchange Information with a View to Standardizing Review Guidelines for Regenerative Medicines
July 17, 2013
-
REGULATORY Health Ministry to Set Up Committee on Diovan Studies, Compile Preventive Measures for Clinical Data Manipulation
July 16, 2013
-
REGULATORY MHLW Presses Kyoto Prefectural University of Medicine to Carry on Diovan Probe
July 16, 2013
ページ
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…